10-Q: Nu Skin Q3 2025: EPS Up, Revenue Down Amid Restructuring

Nu Skin Enterprises reports increased Q3 2025 earnings per share driven by cost management and a business sale, despite a significant decline in overall revenue and customer metrics.

Summary

• Revenue for the three months ended September 30, 2025, decreased 15% to $364.2 million, compared to $430.1 million in the prior-year period.
• Revenue for the nine months ended September 30, 2025, decreased 13% to $1,114.8 million, compared to $1,286.5 million in the prior-year period.
• Diluted earnings per share (EPS) for Q3 2025 increased to $0.34, compared to $0.17 in the prior-year period.
• Diluted EPS for the first nine months of 2025 increased to $2.91, compared to $(2.23) in the prior-year period, significantly boosted by a $176.2 million pre-tax gain from the sale of the Mavely business.
• Customer, Paid Affiliate, and Sales Leader numbers declined by 10%, 13%, and 19% respectively year-over-year.
• Restructuring and impairment expenses for the nine months ended September 30, 2025, were $25.1 million, primarily from an impairment charge on the BeautyBio asset group.
• The company made net debt payments of $165.0 million in the first nine months of 2025, reducing its term loan and revolving credit facility.
• Cash and cash equivalents increased to $251.787 million as of September 30, 2025, from $186.883 million at December 31, 2024.

Sentiment

Score: 4

Explanation: While EPS and net income improved due to a significant one-time gain from a business sale and effective cost management, the core business shows substantial declines in revenue, customer acquisition, and sales force metrics across most segments. This indicates ongoing operational challenges and macroeconomic headwinds. The debt reduction is positive, but the underlying business trends suggest caution.

Positives

• Diluted EPS increased significantly in Q3 2025 to $0.34 from $0.17 in Q3 2024, and for 9M 2025 to $2.91 from $(2.23) in 9M 2024.
• Net income for Q3 2025 was $17.079 million, up from $8.302 million in Q3 2024, and for 9M 2025 was $145.713 million, a substantial improvement from a net loss of $(110.489) million in 9M 2024.
• A pre-tax gain of $176.2 million was recognized from the sale of the Mavely business in 9M 2025.
• Debt was significantly reduced with $165.0 million in net payments during 9M 2025, including a $115.0 million payment on the term loan facility.
• Cash and cash equivalents, including current investments, increased to $253.0 million as of September 30, 2025, from $198.0 million at December 31, 2024.
• Working capital improved to $293.7 million as of September 30, 2025, compared to $242.0 million at December 31, 2024.
• Operating income for Q3 2025 increased to $21.642 million from $18.231 million in Q3 2024, and for 9M 2025 was $42.519 million, a significant improvement from an operating loss of $(98.504) million in 9M 2024.
• The effective tax rate for Q3 2025 was (6.8)% and 18.1% for 9M 2025, benefiting from $8.1 million of additional research and development credits.
• Latin America markets showed strong growth, with revenue increasing 52.5% year-over-year in Q3 2025, and Customers, Paid Affiliates, and Sales Leaders increasing by 87%, 56%, and 53% respectively.
• LifeDNA revenue grew 181% in Q3 2025 to $3.3 million and 150% in 9M 2025 to $7.9 million, with improved operating margins.
• Gross profit as a percentage of revenue for the Nu Skin business increased to 77.7% in Q3 2025 and 77.3% in 9M 2025, driven by strategic portfolio optimization and a favorable product mix shift.
• Selling expenses as a percentage of revenue decreased for both the threeand nine-month periods ended September 30, 2025.

Negatives

• Total revenue decreased 15% in Q3 2025 and 13% in 9M 2025, reflecting broad declines across most segments.
• Customer numbers declined 10% year-over-year to 746,256.
• Paid Affiliates decreased 13% year-over-year to 130,096.
• Sales Leaders declined 19% year-over-year to 31,150.
• Mainland China revenue decreased 19.8% in Q3 2025 and 19.7% in 9M 2025 due to ongoing macroeconomic factors and a shift to online product marketplaces.
• South Korea revenue decreased 22.1% in Q3 2025 and 21.9% in 9M 2025, impacted by macroeconomic trends, inflationary pressures, and price increases.
• The BeautyBio entity experienced significant revenue declines of 65.1% in Q3 2025 and 59.4% in 9M 2025.
• An unrealized loss on equity investments of $28.1 million was recorded in 9M 2025.
• An impairment charge of $25.1 million was recorded on the BeautyBio asset group in Q1 2025.
• Interest rate swap arrangements matured on July 31, 2025, leading to an increased effective interest rate.
• General and administrative expenses as a percentage of revenue increased to 28.8% for Q3 2025 (from 26.9%) and 29.1% for 9M 2025 (from 27.8%).

Risks

• Continued macroeconomic challenges, including inflationary pressures and decreased consumer spending, negatively impacting customer acquisition and sales.
• Headwinds from the ongoing business transformation process and enhancements to the sales performance plan causing disruption for the sales force.
• Uncertainty surrounding tariffs, import/export regulations, and trade disputes, which could increase customs expenses, impact product pricing, reduce demand, or disrupt the supply chain.
• Government regulations pertaining to product formulation, labeling, packaging, product claims, advertising, and the direct selling system, with potential for non-compliance or adverse changes.
• Challenges from foreign tax and customs authorities, potentially leading to additional tax liabilities or disputes.
• Delays or restrictions in repatriating cash from certain foreign markets, such as Mainland China and Argentina, due to government-approval or other requirements.
• Fluctuations in foreign currency exchange rates, which can significantly impact reported revenue and earnings.
• Involvement in legal proceedings, investigations, and other regulatory matters, which, while not currently expected to be material, could have adverse effects.
• Seasonality and cyclicality impacting revenue, particularly during major cultural events (e.g., Asian New Year in Q1) and traditional vacation periods (Q3).

Future Outlook

The company anticipates nominal revenue from Prysm iO intelligent wellness platform device sales in 2025 due to the timing of a limited leader preview. It also expects nominal revenue from the India market pre-opening in Q4 2025, with a formal launch planned for the second half of 2026. Capital expenditures for 2025 are estimated to be approximately $30-35 million, focusing on Rhyz plant expansion, computer systems, software, and facility upgrades. The board of directors is expected to continue declaring quarterly cash dividends, funded by cash flows from operations. The company estimates approximately $2 million of incremental cost pressure for the full year 2025 due to tariffs and does not expect the One Big Beautiful Bill Act (OBBBA) or the Pillar Two Global Minimum Tax to have a material impact on its total tax provision for 2025. Remaining payments under the 2023 restructuring plan are anticipated in Q4 2025. The company is evaluating strategic opportunities with LifeDNA, including potential divestiture.

Management Comments

• "Our priorities for 2025 focus on business model optimization, driven by the continued rollout of enhancements to our sales performance plan, a limited preview of our Prysm iO intelligent wellness platform and business expansion into India."
• "The declines for the third quarter and first nine months of 2025 were largely driven by the continued macroeconomic challenges we have been facing in our markets, which have negatively impacted consumer spending and customer acquisition."
• "While we believe we continue to make progress on our long-term vision, we have experienced headwinds from the transformation process."
• "We are currently evaluating strategic opportunities with LifeDNA, including potentially divesting it, to maximize our return on investment."

Industry Context

The company operates within a challenging global economic environment, facing macroeconomic headwinds such as inflationary pressures and decreased consumer spending, which have negatively impacted customer acquisition and sales across most geographic segments, particularly Mainland China, South Korea, Europe & Africa, and Hong Kong/Taiwan. There is also a noted shift in consumer demand towards online product marketplaces, posing a challenge to the traditional direct selling model. In response, the company is implementing business model optimization, including enhancements to its sales performance plan and a 'developing market strategy' to expand its customer base, as demonstrated by growth in Latin America.

Legal Proceedings

• The company is subject to government regulations pertaining to product formulation, labeling, packaging, product claims, advertising, and its direct selling system, with potential for material adverse effects from non-compliance or changes in regulations.
• Subject to audits by federal, state, and foreign tax authorities, which may result in additional tax liabilities.
• Involved in litigation, investigations, and other proceedings arising in the ordinary course of business, though management believes ultimate liability is not likely to have a material adverse effect.

Stakeholder Impact

• Shareholders: Positive impact from increased EPS (though largely from a one-time gain), continued quarterly cash dividends, and ongoing stock repurchase program. Negative impact from declining revenue and customer base, and potential for future operational challenges to affect stock value.
• Employees: Workforce reductions as part of the 2023 restructuring plan.
• Customers: Impacted by macroeconomic factors, inflationary pressures, and price increases in certain markets, leading to decreased purchasing power and declining customer numbers.
• Sales Force (Paid Affiliates, Sales Leaders): Significant declines in numbers (13% and 19% respectively), disruption from sales performance plan enhancements, and challenges in customer acquisition.
• Creditors: Positive impact from significant debt reduction and compliance with all debt covenants.

Next Steps

• Continue the rollout of enhancements to the sales performance plan.
• Conduct a limited preview of the Prysm iO intelligent wellness platform.
• Proceed with business expansion into India, with a formal launch targeted for H2 2026.
• Execute the full launch of the relaunched Tru Face line in Mainland China in December 2025.
• Evaluate strategic opportunities with LifeDNA, including potential divestiture, to maximize return on investment.
• Anticipate making the remaining payments under the 2023 restructuring plan in Q4 2025.
• Continue to evaluate the impacts of the One Big Beautiful Bill Act (OBBBA) on financial statements.
• Monitor and plan proactive measures to minimize the potential impact of tariffs.
• The board of directors anticipates continuing to declare quarterly cash dividends.

Key Dates

Recommendation

While the company reported a significant increase in net income and EPS for the nine-month period, this was largely driven by a one-time gain from the sale of the Mavely business. The core operational performance shows substantial declines in revenue, customer base, and sales force across most segments, indicating ongoing macroeconomic headwinds and internal transformation challenges. The debt reduction and continued dividends are positive, but the underlying business trends suggest caution. Investors should hold and monitor the effectiveness of strategic initiatives like Prysm iO and India expansion, as well as the impact of macroeconomic conditions on core sales.

Keywords

Nu Skin, NUS, Quarterly Report, SEC Filing, Financial Results, Earnings, Revenue, Direct Selling, Beauty, Wellness, Rhyz, Mavely, BeautyBio, LifeDNA, Restructuring, Debt Reduction, Capital Expenditures, Dividends, Stock Repurchase, China Market, Latin America Growth, Prysm iO, India Expansion, Macroeconomic Challenges, Sales Force Decline